BR112022025480A2 - Composições e métodos para superar a resistência mediada por microambiente por meio de direcionamento de e-selectina - Google Patents
Composições e métodos para superar a resistência mediada por microambiente por meio de direcionamento de e-selectinaInfo
- Publication number
- BR112022025480A2 BR112022025480A2 BR112022025480A BR112022025480A BR112022025480A2 BR 112022025480 A2 BR112022025480 A2 BR 112022025480A2 BR 112022025480 A BR112022025480 A BR 112022025480A BR 112022025480 A BR112022025480 A BR 112022025480A BR 112022025480 A2 BR112022025480 A2 BR 112022025480A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- microenvironment
- compositions
- overcome
- mediated resistance
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940075628 hypomethylating agent Drugs 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 229940123546 E-selectin antagonist Drugs 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038856P | 2020-06-14 | 2020-06-14 | |
| US202063060605P | 2020-08-03 | 2020-08-03 | |
| US202063198856P | 2020-11-17 | 2020-11-17 | |
| PCT/US2021/036992 WO2021257398A1 (en) | 2020-06-14 | 2021-06-11 | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022025480A2 true BR112022025480A2 (pt) | 2023-01-17 |
Family
ID=76731129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025480A BR112022025480A2 (pt) | 2020-06-14 | 2021-06-11 | Composições e métodos para superar a resistência mediada por microambiente por meio de direcionamento de e-selectina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230218649A1 (enExample) |
| EP (1) | EP4164655A1 (enExample) |
| JP (1) | JP2023529485A (enExample) |
| KR (1) | KR20230024402A (enExample) |
| CN (1) | CN116033907A (enExample) |
| AU (1) | AU2021292458A1 (enExample) |
| BR (1) | BR112022025480A2 (enExample) |
| CA (1) | CA3181278A1 (enExample) |
| IL (1) | IL298977A (enExample) |
| MX (1) | MX2022015894A (enExample) |
| WO (1) | WO2021257398A1 (enExample) |
| ZA (1) | ZA202213322B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250100273A (ko) * | 2023-12-26 | 2025-07-03 | 서울대학교병원 | 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2264043T3 (pl) | 2005-09-02 | 2018-04-30 | Glycomimetics, Inc. | Heterobifunkcyjne inhibitory pan-selektyny |
| WO2009073911A1 (en) | 2007-12-10 | 2009-06-18 | Mater Medical Research Institute | Treatment and prophylaxis |
| CA2760292A1 (en) | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| KR102055958B1 (ko) * | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
| WO2015048616A1 (en) * | 2013-09-30 | 2015-04-02 | Glycomimetics, Inc. | Methods and compositions for treating and/or preventing mucositis |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| US20200171005A9 (en) | 2015-12-02 | 2020-06-04 | Glycomimetics, Inc. | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker |
| AU2017341065B2 (en) | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
| JP7275131B2 (ja) * | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| KR20200128025A (ko) * | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2020219419A1 (en) | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Multimeric pan–selectin antagonists |
| JP2022529806A (ja) | 2019-04-24 | 2022-06-24 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 |
| US20220265691A1 (en) | 2019-07-12 | 2022-08-25 | Glycomimetics, Inc. | Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types |
-
2021
- 2021-06-11 AU AU2021292458A patent/AU2021292458A1/en not_active Abandoned
- 2021-06-11 CA CA3181278A patent/CA3181278A1/en active Pending
- 2021-06-11 US US18/001,614 patent/US20230218649A1/en active Pending
- 2021-06-11 IL IL298977A patent/IL298977A/en unknown
- 2021-06-11 WO PCT/US2021/036992 patent/WO2021257398A1/en not_active Ceased
- 2021-06-11 CN CN202180056345.7A patent/CN116033907A/zh active Pending
- 2021-06-11 KR KR1020237001653A patent/KR20230024402A/ko active Pending
- 2021-06-11 MX MX2022015894A patent/MX2022015894A/es unknown
- 2021-06-11 JP JP2022576447A patent/JP2023529485A/ja active Pending
- 2021-06-11 EP EP21736926.3A patent/EP4164655A1/en active Pending
- 2021-06-11 BR BR112022025480A patent/BR112022025480A2/pt not_active Application Discontinuation
-
2022
- 2022-12-08 ZA ZA2022/13322A patent/ZA202213322B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021257398A1 (en) | 2021-12-23 |
| CN116033907A (zh) | 2023-04-28 |
| CA3181278A1 (en) | 2021-12-23 |
| EP4164655A1 (en) | 2023-04-19 |
| MX2022015894A (es) | 2023-01-24 |
| ZA202213322B (en) | 2024-04-24 |
| KR20230024402A (ko) | 2023-02-20 |
| AU2021292458A1 (en) | 2023-01-19 |
| US20230218649A1 (en) | 2023-07-13 |
| IL298977A (en) | 2023-02-01 |
| JP2023529485A (ja) | 2023-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| PH12022553530A1 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| BR112018069251A2 (pt) | métodos de intervenção precoce para prevenir ou melhorar a toxicidade | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| BR112017008042A2 (pt) | métodos e composições para dosagem em terapia de célula adotiva | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| CL2015002968A1 (es) | Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv. | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| WO2019126739A8 (en) | Pyrvinium pamoate anti-cancer therapies | |
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
| MX2020000265A (es) | Composiciones para la administración parenteral de agentes terapéuticos. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112012009250A2 (pt) | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112019002689A2 (pt) | terapia com rapamicina tópica | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |